Public Summary

Summary for ARTG Entry:	351927	Opti Active D
ARTG entry for	Medicine Listed	
Sponsor	Factors Group Australia Pty Ltd	
Postal Address	Unit B 10-16 South Street, Rydalmere, NSW, 2116 Australia	
ARTG Start Date	18/12/2020	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Opti Active D

Product Type	Single Medicine Product	**Effective Date**	8/02/2021

Permitted Indications

Maintain/support healthy teeth

Maintain/support bone health

Maintain/support bone health in post-menopausal women

Aids/assists healthy bone development/growth/building

Maintain/support bone mass/density/integrity

Maintain/support bone mass/density/integrity in post-menopausal women

Maintain/support bone strength

Maintain/support bone strength in post-menopausal women

Help maintain/support bone mineralisation

Vitamin D helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life

Maintain/support immune system health

Enhance/improve/promote immune defence/immunity

Maintain/support healthy immune system function

Maintain/support immune system to fight illness

Enhance/improve/promote/increase (state vitamin/mineral/nutrient) levels in the body

Maintain/support (state vitamin/mineral/nutrient) levels in the body

Helps prevent dietary (state vitamin/mineral/nutrient) deficiency

Maintains/support healthy foetal development

Maintain/support healthy pregnancy

Indication Requirements

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Label statement: Advise your doctor of any medicine you take during pregnancy, particularly in your first trimester.

Indication only for use for medicines that contain vitamin D as an active ingredient. The medicines may only contain a maximum recommended daily dose

This is not an ARTG Certificate document.
The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.
Visit www.tga.gov.au for contact information

Public Summary

of 25 micrograms or less of vitamin D and as a minimum, also contain at least 25% of the RDI in the recommended daily dose of vitamin D.

Product presentation must not imply or refer to serious immunological diseases.

If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

The medicine should not be taken in combination with supplements containing Vitamin D without medical advice (or words to that effect).

Calcifediol may have similar effects to Vitamin D. Consult your health care professional before taking in combination with other medicines.

Use in children under 9 years is not recommended.

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule

Components

1 . Formulation 1

Dosage Form	Tablet, uncoated
Route of Administration	Oral
Visual Identification	

Active Ingredients

calcifediol monohydrate	**.01 mg**

Other Ingredients (Excipients)

calcium hydrogen phosphate dihydrate

croscarmellose sodium

crospovidone

dl-alpha-tocopherol

magnesium stearate

medium chain triglycerides

microcrystalline cellulose

silicon dioxide

sodium ascorbate

starch sodium octenyl succinate

sucrose

Public Summary

Page 2 of 2   Produced at 31.08.2021 at 01:02:10 AEST

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information